Unmet needs in relapsed/refractory mantle cell lymphoma (r/r MCL) post-covalent Bruton tyrosine kinase inhibitor (BTKi): a systematic literature review and meta-analysis

References

• Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl. 4):iv62–iv71. doi:10.1093/annonc/mdx223
   PubMedGoogle Scholar
• Zhou Y, Wang H, Fang W, et al. Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer. 2008;113(4):791–798. doi:10.1002/cncr.23608
   PubMed Web of Science ®Google Scholar
• Epperla N, Hamadani M, Fenske TS, et al. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2018;181(5):703–706. doi:10.1111/bjh.14699
   PubMed Web of Science ®Google Scholar
• Aschebrook-Kilfoy B, Caces DBD, Ollberding NJ, et al. An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma. 2013;54(8):1677–1683. doi:10.3109/10428194.2012.760041
   PubMed Web of Science ®Google Scholar
• Silkenstedt E, Linton K, Dreyling M. Mantle cell lymphoma – advances in molecular biology, prognostication and treatment approaches. Br J Haematol. 2021;195(2):162–173. doi:10.1111/bjh.17419
   PubMed Web of Science ®Google Scholar
• Kumar A, Eyre TA, Lewis KL, et al. New directions for mantle cell lymphoma in 2022. Am Soc Clin Oncol Educ Book. 2022;42:1–15. doi:10.1200/EDBK_349509
   PubMedGoogle Scholar
• Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558–565. doi:10.1182/blood-2007-06-095331
   PubMed Web of Science ®Google Scholar
• Scheubeck G, Jiang L, Hermine O, et al. Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia. 2023;37(9):1887–1894. doi:10.1038/s41375-023-01977-y
   PubMedGoogle Scholar
• Al-Mansour M. Treatment landscape of relapsed/refractory mantle cell lymphoma: an updated review. Clin Lymphoma Myeloma Leuk. 2022;22(11):e1019–e1031. doi:10.1016/j.clml.2022.07.017
   PubMed Web of Science ®Google Scholar
• Stephens DM, Spurgeon SE. Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion. Ther Adv Hematol. 2015;6(5):242–252. doi:10.1177/2040620715592569
   PubMedGoogle Scholar
• Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–516. doi:10.1056/NEJMoa1306220
   PubMed Web of Science ®Google Scholar
• Zhou K, Zou D, Zhou J, et al. Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. J Hematol Oncol. 2021;14(1):167. doi:10.1186/s13045-021-01174-3
   PubMed Web of Science ®Google Scholar
• Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–667. doi:10.1016/S0140-6736(17)33108-2
   PubMed Web of Science ®Google Scholar
• Cheah CY, Chihara D, Romaguera JE, et al. Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol. 2015;26(6):1175–1179. doi:10.1093/annonc/mdv111
   PubMed Web of Science ®Google Scholar
• Burger JA. Bruton tyrosine kinase inhibitors: present and future. Cancer J. 2019;25(6):386–393. doi:10.1097/PPO.0000000000000412
   PubMed Web of Science ®Google Scholar
• Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209–1213. doi:10.1200/JCO.2008.19.6121
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–1342. doi:10.1056/NEJMoa1914347
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA approves brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma; 2020. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-brexucabtagene-autoleucel-relapsed-or-refractory-mantle-cell-lymphoma
   Google Scholar
• O'Reilly MA, Sanderson R, Wilson W, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real-world outcomes in the United Kingdom. Blood. 2022;140(Suppl. 1):7519–7521. doi:10.1182/blood-2022-165031
   Google Scholar
• Mohty R, Kharfan-Dabaja MA. CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma. Ther Adv Hematol. 2022;13:20406207221142133.doi:10.1177/20406207221142133
   Web of Science ®Google Scholar
• Shaw ML. Second-generation BTK inhibitors hit the treatment bullseye with fewer off-target effects. Am J Manag Care. 2020;26(7 Spec No.):SP226–SP227. doi:10.37765/ajmc.2020.88475
   PubMedGoogle Scholar
• IQWIG general methods. Version 6.1. Germany: Institute for Quality and Efficiency in Health Care; 2022.
   Google Scholar
• Dreyling M, Shah B, Wu JJ, et al. Efficacy outcomes following treatment with Bruton tyrosine kinase inhibitors (BTKI) for relapsed/refractory mantle cell lymphoma (R/R MCL): a literature-based meta-analysis. Value Health. 2022;25(7):S609–S610. doi:10.1016/j.jval.2022.04.1695
   Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339(1):b2700. doi:10.1136/bmj.b2700
   PubMed Web of Science ®Google Scholar
• Guyot P, Ades AE, Ouwens MJNM, et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12(1):9. doi:10.1186/1471-2288-12-9
   PubMed Web of Science ®Google Scholar
• Cope S, Chan K, Jansen JP. Multivariate network meta-analysis of survival function parameters. Res Synth Methods. 2020;11(3):443–456. doi:10.1002/jrsm.1405
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560. doi:10.1136/bmj.327.7414.557
   PubMed Web of Science ®Google Scholar
• Martin P, Maddocks K, Leonard JP, et al. Postibrutinib outcomes in patients with mantle cell lymphoma. Blood. 2016;127(12):1559–1563. doi:10.1182/blood-2015-10-673145
   PubMed Web of Science ®Google Scholar
• Rai S, Tanizawa Y, Cai Z, et al. Outcomes for recurrent mantle cell lymphoma post-ibrutinib therapy: a retrospective cohort study from a Japanese Administrative Database. Adv Ther. 2022;39(10):4792–4807. doi:10.1007/s12325-022-02258-3
   PubMed Web of Science ®Google Scholar
• Rai S, Tanizawa Y, Cai Z, et al. MCL-041: outcomes for recurrent mantle cell lymphoma post-BTK inhibitor therapy in Japan: an administrative database study. Clin Lymph Myeloma Leuk. 2021;21(Suppl. 1):S407–S408. doi:10.1016/S2152-2650(21)01918-2
   Google Scholar
• Yi JH, Kim SJ, Yoon DH, et al. Real-world outcomes of ibrutinib therapy in Korean patients with relapsed or refractory mantle cell lymphoma: a multicenter, retrospective analysis. Cancer Commun. 2021;41(3):275–278. doi:10.1002/cac2.12150
   Web of Science ®Google Scholar
• Regny C, Oberic L, Guillaume M, et al. Clinical efficacy of the RIBVD regimen for refractory/relapsed (R/R) mantle cell lymphoma (MCL) patients: a retrospective study of the LYSA Group. HemaSphere. 2019;3(S1):193. doi:10.1002/j.2572-9241.2019.tb00081.x
   Google Scholar
• Wang M, Schuster SJ, Phillips T, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171. doi:10.1186/s13045-017-0537-5
   PubMedGoogle Scholar
• Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387(10020):770–778. doi:10.1016/S0140-6736(15)00667-4
   PubMed Web of Science ®Google Scholar
• Jain P, Kanagal-Shamanna R, Zhang S, et al. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. Am J Hematol. 2021;96(5):E137–E140. doi:10.1002/ajh.26109
   PubMed Web of Science ®Google Scholar
• Jain P, Zhang S, Kanagal-Shamanna R, et al. Outcomes of acalabrutinib failures in relapsed mantle cell lymphoma. Blood. 2020;136(Suppl. 1):9–10. doi:10.1182/blood-2020-137440
   Google Scholar
• Jain P, Kanagal-Shamanna R, Zhang S, et al. Outcomes, causes of discontinuation and mutation profile of patients with mantle cell lymphoma who progressed on acalabrutinib. Blood. 2018;132(Suppl. 1):4151. doi:10.1182/blood-2018-99-115179
   Google Scholar
• Jain P, Kanagal-Shamanna R, Zhang S, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578–587. doi:10.1111/bjh.15567
   PubMed Web of Science ®Google Scholar
• Jain P, Zhao S, Kanagal-Shamanna R, et al. Non-Bcl2 mutations are predominant in patients (pts) with venetoclax resistant mantle cell lymphoma (MCL) – response and clinical outcomes in ultra-refractory MCL. Blood. 2019;134(Suppl. 1):2815. doi:10.1182/blood-2019-126175
   Google Scholar
• Zhao S, Kanagal-Shamanna R, Navsaria L, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) – outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95(6):623–629. doi:10.1002/ajh.25796
   PubMed Web of Science ®Google Scholar
• Tucker D, Morley N, MacLean P, et al. The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma. Br J Haematol. 2021;192(6):1035–1038. doi:10.1111/bjh.16739
   PubMed Web of Science ®Google Scholar
• Tucker D, Morley N, Vandenburghe E, et al. Five years on: a real-world observational study of patients receiving ibrutinib for relapsed/refractory MCL from the UK and Ireland. Br J Haematol. 2020;189(Suppl. 1):29.
   Google Scholar
• Eyre TA, Walter HS, Iyengar S, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica. 2019;104(2):E68–E71. doi:10.3324/haematol.2018.198812
   PubMed Web of Science ®Google Scholar
• Cencini E, Mecacci B, Morelli F, et al. Ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma Network). Am J Blood Res. 2021;11(4):373–383.
   PubMedGoogle Scholar
• Hess G, Dreyling M, Oberic L, et al. Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: the SCHOLAR-2 retrospective chart review study. Br J Haematol. 2022;202(4):749–759. doi:10.1111/bjh.18519
   PubMed Web of Science ®Google Scholar
• Di M, Long JB, Kothari SK, et al. Real-world practice patterns and outcomes following Bruton tyrosine kinase inhibitors (BTKi) in older patients with mantle cell lymphoma (MCL): a population-based analysis. Blood. 2022;140(Suppl. 1):10904–10906. doi:10.1182/blood-2022-164959
   Google Scholar
• McCulloch R, Lewis D, Crosbie N, et al. Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. Br J Haematol. 2021;193(2):290–298. doi:10.1111/bjh.17363
   PubMed Web of Science ®Google Scholar
• McCulloch R, Rule S, Eyre T, et al. Ibrutinib at first relapse for mantle cell lymphoma: a United Kingdom real world analysis of outcomes in 185 Patients. Br J Haematol. 2020;189(Suppl. 1):104–105.
   Google Scholar
• McCulloch R, Rule S, Eyre TA, et al. Ibrutinib at first relapse for mantle cell lymphoma: a United Kingdom real world analysis of outcomes in 169 patients. Blood. 2019;134(Suppl. 1):3993. doi:10.1182/blood-2019-125947
   Google Scholar
• McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020;189(4):684–688. doi:10.1111/bjh.16416
   PubMed Web of Science ®Google Scholar
• McCulloch R, Visco C, Frewin R, et al. R-BAC maintains high response rate in mantle cell lymphoma following relapse on BTK inhibitor therapy. Blood. 2019;134(Suppl. 1):3989. doi:10.1182/blood-2019-129829
   Google Scholar
• Sawalha Y, Goyal S, Switchenko JM, et al. Outcomes of patients with relapsed mantle cell lymphoma treated with venetoclax: a multicenter retrospective analysis. Blood. 2020;136(Suppl. 1):4–6. doi:10.1182/blood-2020-138878
   PubMedGoogle Scholar
• Epperla N, Hamadani M, Cashen AF, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a "real world" study. Hematol Oncol. 2017;35(4):528–535. doi:10.1002/hon.2380
   PubMed Web of Science ®Google Scholar
• Rai S, Hess L, Chen Y, et al. Outcomes for patients with mantle cell lymphoma post-CBTK inhibitor therapy in the United States and Japan: a study of two real-world databases. HemaSphere. 2022;6(Suppl. 3):1024–1025. doi:10.1097/01.HS9.0000847404.28922.1a
   Google Scholar
• Rai S, Hess LM, Chen Y, et al. Outcomes for patients with mantle cell lymphoma post-covalent BTK inhibitor therapy in the United States and Japan: a study of two real-world databases. Blood. 2021;138(Suppl. 1):4523. doi:10.1182/blood-2021-148265
   Google Scholar
• Jerkeman M, Kolstad A, Hutchings M, et al. Venetoclax, lenalidomide and rituximab for patients with relapsed or refractory mantle cell lymphoma – the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial. Blood. 2022;140(Suppl. 1):184–185. doi:10.1182/blood-2022-155654
   PubMedGoogle Scholar
• Locke F, Hu ZH, Gerson J, et al. Real-world outcomes of brexucabtagene autoleucel (Brexu-Cel) for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States (US). HemaSphere. 2022;6(Suppl. 3):1336–1337. doi:10.1097/01.HS9.0000848672.43673.8a
   Google Scholar
• Herbaux C, Bret C, Di Blasi R, et al. Kte-x19 in relapsed or refractory mantle-cell lymphoma, a ‘real-life’ study from the DESCAR-T Registry and LYSA Group. Blood. 2021;138(Suppl. 1):743. doi:10.1182/blood-2021-148626
   PubMedGoogle Scholar
• Iacoboni G, Rejeski K, Camacho L, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood. 2021;138(Suppl. 1):2827. doi:10.1182/blood-2021-153087
   Google Scholar
• Iacoboni G, Rejeski K, Villacampa G, et al. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6(12):3606–3610. doi:10.1182/bloodadvances.2021006922
   PubMed Web of Science ®Google Scholar
• Romancik JT, Goyal S, Gerson JN, et al. Analysis of outcomes and predictors of response in patients with relapsed mantle cell lymphoma treated with brexucabtagene autoleucel. Blood. 2021;138(Suppl. 1):1756. doi:10.1182/blood-2021-153277
   Google Scholar
• Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023;41(14):2594–2606.
   PubMed Web of Science ®Google Scholar
• Jain P, Wang Y, Locke FL, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real-world experience from the United States lymphoma CAR T consortium. J Clin Oncol. 2022;40(16 Suppl.):e19583. doi:10.1200/JCO.2022.40.16_suppl.e19583
   Web of Science ®Google Scholar
• Wang Y, Jain P, Locke F, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma in routine practice: updated report from the US Lymphoma CAR T Consortium. HemaSphere. 2022;6(Suppl. 3):1042–1043. doi:10.1097/01.HS9.0000847488.86807.da
   Google Scholar
• Wang Y, Jain P, Locke FL, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US Lymphoma CAR T Consortium. Blood. 2021;138(Suppl. 1):744. doi:10.1182/blood-2021-147563
   PubMedGoogle Scholar
• Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2022;41(3):555–567. doi:10.1200/JCO.21.02370
   PubMed Web of Science ®Google Scholar
• Munoz J, Reagan PM, Goy AH, et al. Assessment of durable responses after brexucabtagene autoleucel (KTE-X19) in the ZUMA-2 study in relapsed/refractory mantle cell lymphoma (R/R MCL). Blood. 2022;140(Suppl. 1):9320–9322. doi:10.1182/blood-2022-158097
   Google Scholar
• Wang ML, Munoz J, Goy AH, et al. One-year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients (Pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL). Transplant Cell Ther. 2021;27(3):S342. doi:10.1016/S2666-6367(21)00440-1
   Google Scholar
• Wang ML, Munoz J, Goy A, et al. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL): results of the Phase 2 ZUMA-2 Study. Blood. 2019;134(Suppl. 1):754. doi:10.1182/blood-2019-126064
   Web of Science ®Google Scholar
• Wang ML, Rossi JM, Munoz J, et al. Pharmacological profile and clinical outcomes of KTE-X19 by prior Bruton tyrosine kinase inhibitor (BTKi) exposure or mantle cell lymphoma (MCL) morphology in patients (Pts) with relapsed/refractory (R/R) MCL in the ZUMA-2 Trial. Transplant Cell Ther. 2021;27(3):S341–S342. doi:10.1016/S2666-6367(21)00439-5
   Google Scholar
• Wang Y, Munoz J, Goy A, et al. One-year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma. Blood. 2020;136(Suppl. 1):20–22. doi:10.1182/blood-2020-136382
   Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed/refractory mantle cell lymphoma (R/R MCL): results from Phase 2 of ZUMA-2. Mol Ther. 2020;28(4 Suppl. 1):573.
   Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T cell therapy, in patients (Pts) with relapsed/refractory mantle cell lymphoma (R/R MCL): results of the Phase 2 ZUMA-2 Study. Biol Blood Marrow Transplant. 2020;26(3):S1. doi:10.1016/j.bbmt.2019.12.135
   PubMed Web of Science ®Google Scholar
• Wang M, Rossi JM, Munoz J, et al. Pharmacological profile and clinical outcomes of KTE-X19 by prior Bruton tyrosine kinase inhibitor (BTKi) exposure or mantle cell lymphoma (MCL) morphology in patients with relapsed/refractory (R/R) MCL in the ZUMA-2 Trial. Blood. 2020;136(Suppl. 1):29. doi:10.1182/blood-2020-136831
   Google Scholar
• Wang M, Rossi JM, Munoz J, et al. Pharmacological profile and clinical outcomes of KTE-X19 by prior Bruton tyrosine kinase inhibitor exposure or mantle cell lymphoma morphology in patients with relapsed/refractory mantle cell lymphoma in the ZUMA-2 trial. Br J Haematol. 2021;193(Suppl. 1):43–44.
   PubMedGoogle Scholar
• National Comprehensive Cancer Network. Mantle cell lymphoma. Plymouth (PA): National Comprehensive Cancer Network; 2021.
   Google Scholar
• Burkart M, Karmali R. Relapsed/refractory mantle cell lymphoma: beyond BTK inhibitors. J Pers Med. 2022;12(3):376. doi:10.3390/jpm12030376
   PubMed Web of Science ®Google Scholar
• Jain P, Dreyling M, Seymour JF, et al. High-risk mantle cell lymphoma: definition, current challenges, and management. J Clin Oncol. 2020;38(36):4302–4316. doi:10.1200/JCO.20.02287
   PubMed Web of Science ®Google Scholar
• Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017;179(3):430–438. doi:10.1111/bjh.14870
   PubMed Web of Science ®Google Scholar
• Rule S, Dreyling M, Goy A, et al. Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. Haematologica. 2019;104(5):e211–e214. doi:10.3324/haematol.2018.205229
   PubMed Web of Science ®Google Scholar
• Wang ML, Lee H, Chuang H, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56. doi:10.1016/S1470-2045(15)00438-6
   PubMed Web of Science ®Google Scholar
• Wang M, Munoz J, Goy A, et al. Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24). J Clin Oncol. 2021;39(15 Suppl.):7547. doi:10.1200/JCO.2021.39.15_suppl.7547
   Web of Science ®Google Scholar
• Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2021;386(7):640–654. doi:10.1056/NEJMoa2116133
   PubMed Web of Science ®Google Scholar
• Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396(10254):839–852. doi:10.1016/S0140-6736(20)31366-0
   PubMed Web of Science ®Google Scholar
• Dreyling M, Doorduijn JK, Gine E, et al. Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network. Blood. 2022;140(Suppl. 1):1–3. doi:10.1182/blood-2022-163018
   PubMedGoogle Scholar
• Giné E, Medina-Herrera A, Cruz F, et al. Five-year update of the first-line imcl-2015 GELTAMO study. Prolonged molecular and clinical responses were observed after MRD-driven ibrutinib discontinuation. Hematol Oncol. 2023;41(S2):148–150. doi:10.1002/hon.3163_98
   Google Scholar
• Arcari A, Morello L, Vallisa D, et al. Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi. Leuk Lymphoma. 2021;62(14):3474–3483. doi:10.1080/10428194.2021.1961238
   PubMed Web of Science ®Google Scholar
• Lew TE, Cliff ERS, Dickinson M, et al. T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease. Bone Marrow Transplant. 2021;56(11):2857–2859. doi:10.1038/s41409-021-01418-3
   PubMed Web of Science ®Google Scholar
• Ip A, Della Pia A, Goy AH. SOHO state of the art updates and next questions: treatment evolution of mantle cell lymphoma: navigating the different entities and biological heterogeneity of mantle cell lymphoma in 2024. Clin Lymphoma Myeloma Leuk. 2024. doi:10.1016/j.clml.2024.02.010
   Google Scholar